Minireviews
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2021; 27(31): 5181-5188
Published online Aug 21, 2021. doi: 10.3748/wjg.v27.i31.5181
Screening and prevention of hepatitis C virus reactivation during chemotherapy
Yuan-Rung Li, Tsung-Hui Hu, Wen-Chi Chen, Ping-I Hsu, Hui-Chun Chen
Yuan-Rung Li, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan
Tsung-Hui Hu, Department of Internal Medicine, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
Wen-Chi Chen, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung 813, Taiwan
Ping-I Hsu, Division of Gastroenterology and Hepatology, Department of Internal Medicine, An Nan Hospital, China Medical University, Tainan 709, Taiwan
Hui-Chun Chen, Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan
Author contributions: Li YR developed the theory and performed the computations; Chen WC and Hsu PI verified the analytical methods; Hu TH, Chen HC and Hsu PI supervised the findings of this work; all authors discussed the results and contributed to the final manuscript.
Conflict-of-interest statement: All authors have and declare that there are no other relationships or activities that could appear to have influenced the submitted work.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ping-I Hsu, PhD, Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, An Nan Hospital, China Medical University, No. 66, Sec. 2, Changhe Rd, Tainan 709, Taiwan. williamhsup@yahoo.com.tw
Received: January 28, 2021
Peer-review started: January 28, 2021
First decision: May 2, 2021
Revised: May 23, 2021
Accepted: August 2, 2021
Article in press: August 2, 2021
Published online: August 21, 2021
Core Tip

Core Tip: Hepatitis C virus (HCV) reactivation occurs in approximately one-fourth of HCV-infected cancer patients receiving chemotherapy. An HCV-related hepatitis flare during chemotherapy may lead to the discontinuation of potentially life-saving chemotherapy. Currently, universal HCV screening is recommended in hematological malignancy patients before chemotherapy, but there is no evidence-based guideline for other cancer patients. direct-acting antivirals treatment can cure HCV infection and prevent HCV reactivation during chemotherapy.